Obesity Advancements: Ascletis’ Combo Trial, Mazdutide’s NEJM Breakthrough, Novo CEO Exit & more
In this week’s Obesity Updates, we’re spotlighting the latest forces shaping obesity innovation — from cutting-edge clinical trials and major IPOs to industry leadership transitions and groundbreaking data out of China.
Key updates include:
💉 Ascletis launches a U.S. trial combining ASC47 and semaglutide in a once-monthly obesity therapy
📉 Tourmaline Bio shares plunge after its Pacibekitug candidate underdelivers in Phase 2
🧬 Mazdutide’s Phase 3 data published in NEJM, showing up to 80.2 percent liver fat reduction
💰 Hengrui Pharma raises $1.29B via Hong Kong IPO to fund two obesity drug candidates
🔁 Novo Nordisk CEO Lars Jørgensen steps down amid next-gen pipeline pressure from Eli Lilly
Discover how biotech leaders across the U.S., China, and Europe are rewriting the future of obesity treatment through innovation, investment, and disruption.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on Obesity
#ObesityResearch #GLP1Therapies #ObesityTreatment #BiotechNews #Semaglutide #Mazdutide #WeightLossScience #PharmaInnovation #LucidQuest #ClinicalTrials #HealthcareUpdates #NovoNordisk #HengruiPharma